Advertisement

Pneumococcal Infections

  • Keith P. Klugman
  • Charles Feldman
Chapter

The first edition of this chapter was written by the late Maxwell Finland and later versions by Robert S Baltimore, and Eugene D Shapiro. The current authors acknowledge the contributions of their predecessors.

Keywords

Otitis Medium Conjugate Vaccine Invasive Pneumococcal Disease Pneumococcal Disease Pneumococcal Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors wish to thank Rachel Patzer for her many hours spent bringing the references in this chapter into the electronic age.

References

  1. 1.
    Ahonkhai, V. I., S. H. Landesman, et al. (1979). “Failure of pneumococcal vaccine in children with sickle-cell disease.” N Engl J Med 301: 26–7.PubMedGoogle Scholar
  2. 2.
    Almirall, J., C. A. Gonzalez, et al. (1999). “Proportion of community-acquired pneumonia cases attributable to tobacco smoking.” Chest 116: 375–9.PubMedGoogle Scholar
  3. 3.
    Amdahl, B. M., J. B. Rubins, et al. (1995). “Impaired natural immunity to pneumolysin during human immunodeficiency virus infection in the United States and Africa.” Am J Respir Crit Care Med 152: 2000–4.PubMedGoogle Scholar
  4. 4.
    Ammann, A. J., J. Addiego, et al. (1977). “Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy.” N Engl J Med 297: 897–900.PubMedGoogle Scholar
  5. 5.
    Ammann, A. J., G. Schiffman, et al. (1981). “Immunization of immunosuppressed patients with pneumococcal polysaccharide vaccine.” Rev Infect Dis 3 Suppl: S160–7.PubMedGoogle Scholar
  6. 6.
    Andiman, W. A., J. Mezger, et al. (1994). “Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1.” J Pediatr 124 (6): 846–52.PubMedGoogle Scholar
  7. 7.
    Appelbaum, P. C. (1992). “Antimicrobial resistance in Streptococcus pneumoniae: an overview.” Clin Infect Dis 15: 77–83.PubMedGoogle Scholar
  8. 8.
    Appelbaum, P. C., A. Bhamjee, et al. (1977). “Streptococcus pneumoniae resistant to penicillin and chloramphenicol.” Lancet 2:995–7.PubMedGoogle Scholar
  9. 9.
    Arason, V. A., K. G. Kristinsson, et al. (1996). “Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study.” Br Med J 313:387–91.Google Scholar
  10. 10.
    Armstrong, R. R. (1931). “A swift and simple method for deciding pneumococcal “type.” ” Br Med J 1: 214–15.PubMedGoogle Scholar
  11. 11.
    Aspa, J., O. Rajas, et al. (2004). “Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.” Clin Infect Dis 38: 787–98.PubMedGoogle Scholar
  12. 12.
    Austrian, R. (1957). “Pneumococcal endocarditis, meningitis, and rupture of the aortic valve.” Arch Intern Med 99: 539–44.Google Scholar
  13. 13.
    Austrian, R. (1980). Surveillance of Pneumococcal Infection for Field Trials of Polyvalent Pneumococcal Vaccine. B. National Institutes of Health, Bethesda MA.Google Scholar
  14. 14.
    Austrian, R. (1981). “Pneumococcus: the first one hundred years.” Rev Infect Dis 3: 183–9.PubMedGoogle Scholar
  15. 15.
    Austrian, R. (1981). “Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.” Rev Infect Dis 3 Suppl: S1–17.PubMedGoogle Scholar
  16. 16.
    Austrian, R. (1984). “A reassessment of pneumococcal vaccine.” N Engl J Med 310: 651–3.PubMedGoogle Scholar
  17. 17.
    Austrian, R., and Gold, J. (1964). “Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia.” Ann. Intern. Med. 60: 759–776.PubMedGoogle Scholar
  18. 18.
    Austrian, R., R. M. Douglas, et al. (1976). “Prevention of pneumococcal pneumonia by vaccination.” Trans Assoc Am Physicians 89: 184–94.PubMedGoogle Scholar
  19. 19.
    Baddour, L. M., V. L. Yu, et al. (2004). “Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.” Am J Respir Crit Care Med 170: 440–44.PubMedGoogle Scholar
  20. 20.
    Baik, I., G. C. Curhan, et al. (2000). “A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women.” Arch Intern Med 160: 3082–8.PubMedGoogle Scholar
  21. 21.
    Baltimore, R. S. (1992). “New challenges in the development of a conjugate pneumococcal vaccine.” JAMA 268: 3366–7.PubMedGoogle Scholar
  22. 22.
    Beall, B., M. C. McEllistrem, et al. (2006). “Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002.” J Clin Microbiol 44: 999–1017.PubMedGoogle Scholar
  23. 23.
    Benjamin, J. E., Ruegsegger, J. M., and Senior, F. A. (1939). “Cross-infection in pneumococcic pneumonia.” J. Am. Med. Assoc. 112: 1127–1130.Google Scholar
  24. 24.
    Bentley, S. D., D. M. Aanensen, et al. (2006). “Genetic Analysis of the Capsular Biosynthetic Locus from All 90 Pneumococcal Serotypes.” PLoS Genet 2: e31.PubMedGoogle Scholar
  25. 25.
    Bergey, D. H. (1934). A key to the identification of organisms of the class Schizomycetes. Bergey’s Manual of Determinative Bacteriology. Baltimore, Williams & Wilkins: 48.Google Scholar
  26. 26.
    Bernstein, L. J., B. Z. Krieger, et al. (1985). “Bacterial infection in the acquired immunodeficiency syndrome of children.” Pediatr Infect Dis 4: 472–5.PubMedGoogle Scholar
  27. 27.
    Black, S., H. Shinefield, et al. (2004). “Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.” Pediatr Infect Dis J 23: 485–9.PubMedGoogle Scholar
  28. 28.
    Black, S., H. Shinefield, et al. (2000). “Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.” Pediatr Infect Dis J 19: 187–95.PubMedGoogle Scholar
  29. 29.
    Black, S. B., H. R. Shinefield, et al. (2002). “Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.” Pediatr Infect Dis J 21: 810–5.PubMedGoogle Scholar
  30. 30.
    Block, S. L. (1997). “Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media.” Pediatr Infect Dis J 16: 449–56.PubMedGoogle Scholar
  31. 31.
    Bolan, G., C. V. Broome, et al. (1986). “Pneumococcal vaccine efficacy in selected populations in the United States.” Ann Intern Med 104: 1–6.PubMedGoogle Scholar
  32. 32.
    Bonnard, P., F. X. Lescure, et al. (2005). “Community-acquired bacteraemic pneumococcal pneumonia in adults: effect of diminished penicillin susceptibility on clinical outcome.” J Infect 51:69–76.PubMedGoogle Scholar
  33. 33.
    Borgono, J. M., A. A. McLean, et al. (1978). “Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants.” Proc Soc Exp Biol Med 157: 148–54.PubMedGoogle Scholar
  34. 34.
    Briles, D., S. Hollingshead, et al. (2000). “The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.” Vaccine 19: 87–95.Google Scholar
  35. 35.
    Briles, D., S. Hollingshead, et al. (2000). Pneumococcal proteins PspA and PspC: Their potential for use as vaccines. Streptococcus pneumoniae. Molecular Biology and Mechanisms of Disease. A Tomasz. New York, Mary Ann Liebert, Inc: 253–60.Google Scholar
  36. 36.
    Bronzwaer, S., O. Cars, et al. (2002). “A European Study on the Relationship between Antimicrobial Use and Antimicrobial Resistance.” Emerg Infect Dis 8: 278–82.PubMedGoogle Scholar
  37. 37.
    Broome, C. V. (1981). “Efficacy of pneumococcal polysaccharide vaccines.” Rev Infect Dis 3 Suppl: S82–96.PubMedGoogle Scholar
  38. 38.
    Broome, C. V., and R. R. Facklam (1981). “Epidemiology of clinically significant isolates of Streptococcus pneumoniae in the United States.” Rev Infect Dis 3: 277–81.PubMedGoogle Scholar
  39. 39.
    Broome, C. V., R. R. Facklam, et al. (1980). “From the center for disease control. Epidemiology of pneumococcal serotypes in the United States, 1978–1979.” J Infect Dis 141: 119–23.PubMedGoogle Scholar
  40. 40.
    Broome, C. V., R. R. Facklam, et al. (1980). “Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine.” N Engl J Med 303: 549–52.PubMedGoogle Scholar
  41. 41.
    Brown, E. J., S. W. Hosea, et al. (1983). “The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream.” Rev Infect Dis 5 Suppl 4: S797–805.PubMedGoogle Scholar
  42. 42.
    Brown, J. W., and M. Finland. (1939). “A family outbreak of type V pneumococcus infections: clinical, bacteriological and immunological studies.” Ann Intern Med 13: 394–401.Google Scholar
  43. 43.
    Brueggemann, A. B., D. T. Griffiths, et al. (2003). “Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential.” J Infect Dis 187: 1424–32.PubMedGoogle Scholar
  44. 44.
    Brundage, D. K., A. E. Russell, R. R. Jones, J. J. Bloomfield, and R. Thompson (1932). Frequency of pneumonia among iron and steel workers. Public Health Bulletin US Government Printing Office, Washington D.C.: 202.Google Scholar
  45. 45.
    Brundage, J. F. (2006). “Interactions between influenza and respiratory bacterial pathogens: implications for pandemic preparedness.” Lancet Infect Dis 6: 303–12.PubMedGoogle Scholar
  46. 46.
    Brunell, P. A., J. W. Bass, et al. (1985). “American Academy of Pediatrics. Committee on infectious diseases. Recommendations for using pneumococcal vaccine in children.” Pediatrics 75: 1153–8.PubMedGoogle Scholar
  47. 47.
    Buchanan, R. E., and W. E. Gibbons (1974). Bergey’s Manual of Determinative Bacteriology. Baltimore, Williams & Wilkins.Google Scholar
  48. 48.
    Buie, K. A., K. P. Klugman, et al. (2004). “Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes, in HIV-infected and -uninfected adults with pneumococcal bacteremia.” J Infect Dis 189: 1996–2000.PubMedGoogle Scholar
  49. 49.
    Burman, L. A., R. Norrby, et al. (1985). “Invasive pneumococcal infections: incidence, predisposing factors, and prognosis.” Rev Infect Dis 7: 133–42.PubMedGoogle Scholar
  50. 50.
    Butler, J. C., R. F. Breiman, et al. (1993). “Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.” JAMA 270: 1826–31.PubMedGoogle Scholar
  51. 51.
    Byington, C. L., K. Korgenski, et al. (2006). “Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.” Pediatr Infect Dis J 25: 250–4.PubMedGoogle Scholar
  52. 52.
    Byington, C. L., L. Y. Spencer, et al. (2002). “An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations.” Clin Infect Dis 34: 434–40.PubMedGoogle Scholar
  53. 53.
    Caputo, G. M., P. C. Appelbaum, et al. (1993). “Infections due to penicillin-resistant pneumococci. Clinical, epidemiologic, and microbiologic features.[see comment].” Arch Intern Med 153: 1301–10.PubMedGoogle Scholar
  54. 54.
    CDC (1978). “Recommendation of the Public Health Service Advisory Committee on Immunization Practices: Pneumococcal polysaccharide vaccine.” Morbid Mortal Week Rep 27: 25–31.Google Scholar
  55. 55.
    CDC (1979). “Bacterial meningitis and meningococcemia.” Morbid Mortal Week Rep 28: 277–9.Google Scholar
  56. 56.
    CDC (1981). “Recommendations of the Immunization Practices Advisory Committee (ACIP): Pneumococcal polysaccharide vaccine.” Morbid Mortal Week Rep 30: 410–19.Google Scholar
  57. 57.
    CDC (1997). “Recommendations of the Immunization Practices Advisory Committee (ACIP): Prevention of Pneumococcal Disease.” Morbid Mortal Week Rep 46 (suppl.) (RR-8): 1–24.Google Scholar
  58. 58.
    CDC (2000). “Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).” Morbid Mortal WeekRep 49 (RR-9): 1–35.Google Scholar
  59. 59.
    Chen, D. K., A. McGeer, et al. (1999). “Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.” New Engl J Med 341: 233–9.PubMedGoogle Scholar
  60. 60.
    Clemens, J. D., and E. D. Shapiro (1984). “Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials?” Rev Infect Dis 6: 589–600.PubMedGoogle Scholar
  61. 61.
    Cockeran, R., R. Anderson, et al. (2002). “The role of pneumolysin in the pathogenesis of Streptococcus pneumoniae infection.” Curr Opin Infect Dis 15: 235–9.PubMedGoogle Scholar
  62. 62.
    Cockeran, R., R. Anderson, et al. (2003). “Pneumolysin in the immunopathogenesis and treatment of pneumococcal disease.” Expert Rev Anti Infect Ther 1: 231–9.PubMedGoogle Scholar
  63. 63.
    Cole, R., and W. G. MacCallum (1918). “Pneumonia at a base hospital.” JAMA 70: 1146–56.Google Scholar
  64. 64.
    Collins, S. D., and M. Gover (1934). “Age and seasonal incidence of minor respiratory attacks classified according to clinical symptoms.” Am J Hyg 20: 533–54.Google Scholar
  65. 65.
    Coonrod, J. D., and K. Yoneda (1981). “Complement and opsonins in alveolar secretions and serum of rats with pneumonia due to Streptococcus pneumoniae.” Rev Infect Dis 3: 310–22.PubMedGoogle Scholar
  66. 66.
    Cooper, G., C. Rosenstein, A. Walter, and L. Peizer (1932). “The further separation of types among the pneumococci hitherto included in group IV and the development of therapeutic antisera for these types.” J Exp Med 55: 531–54.PubMedGoogle Scholar
  67. 67.
    Cortese, M. M., M. Wolff, et al. (1992). “High incidence rates of invasive pneumococcal disease in the White Mountain Apache population.” Arch Intern Med 152: 2277–82.PubMedGoogle Scholar
  68. 68.
    Crewe-Brown, H. H., A. S. Karstaedt, et al. (1997). “Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes.” Clin Infect Dis 25: 1165–72.PubMedGoogle Scholar
  69. 69.
    Cruickshank, R. (1933). “Pneumococcal infections (Milroy Lectures).” Lancet 1: 563–568, 621–26, 680–85.Google Scholar
  70. 70.
    Cundell, D., H. R. Masure, et al. (1995). “The molecular basis of pneumococcal infection: a hypothesis.” Clin Infect Dis 21 Suppl 3: S204–11.PubMedGoogle Scholar
  71. 71.
    Cutts, F. T., S. M. Zaman, et al. (2005). “Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.” Lancet 365: 1139–46.PubMedGoogle Scholar
  72. 72.
    Dagan, R., D. Engelhard, et al. (1992). “Epidemiology of invasive childhood pneumococcal infections in Israel. The Israeli Pediatric Bacteremia and Meningitis Group.” JAMA 268: 3328–32.PubMedGoogle Scholar
  73. 73.
    Dagan, R., N. Givon-Lavi, et al. (2005). “Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus.” J Infect Dis 192: 367–76.PubMedGoogle Scholar
  74. 74.
    Dagan, R., N. Givon-Lavi, et al. (2003). “Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers.” Pediatr Infect Dis J 22: 532–40.PubMedGoogle Scholar
  75. 75.
    Dagan, R., S. Gradstein, et al. (2000). “An outbreak of Streptococcus pneumoniae serotype 1 in a closed community in southern Israel.” Clin Infect Dis 30: 319–21.PubMedGoogle Scholar
  76. 76.
    Davidson, M., A. J. Parkinson, et al. (1994). “The epidemiology of invasive pneumococcal disease in Alaska, 1986–1990--ethnic differences and opportunities for prevention.” J Infect Dis 170: 368–76.PubMedGoogle Scholar
  77. 77.
    Davidson, R., R. Cavalcanti, et al. (2002). “Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.” New Engl J Med 346: 747–50.PubMedGoogle Scholar
  78. 78.
    Davies, J. A. V. (1937). “The response of infants to inoculation with type 1 pneumococcus carbohydrate.” J. Immunol. 33: 1–7.Google Scholar
  79. 79.
    Dochez, A. R., and L. J. Gillespie (1913). “A biological classification of pneumococci by means of immunity reactions.” JAMA 61: 727–30.Google Scholar
  80. 80.
    Drinker, C. K., and M. E. Field (1933). Lymphatics, Lymph and Tissue Fluid. Baltimore, Williams & Wilkins.Google Scholar
  81. 81.
    du Cheyron, D., A. Lesage, et al. (2003). “Corticosteroids as adjunctive treatment in Austrian’s syndrome (pneumococcal endocarditis, meningitis, and pneumonia): report of two cases and review of the literature.” J Clin Pathol 56: 879–81.PubMedGoogle Scholar
  82. 82.
    Dworkin, M. S., J. W. Ward, et al. (2001). “Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination.” Clin Infect Dis 32: 794–800.PubMedGoogle Scholar
  83. 83.
    Eastham, K. M., R. Freeman, et al. (2004). “Clinical features, aetiology and outcome of empyema in children in the north east of England.” Thorax 59: 522–5.PubMedGoogle Scholar
  84. 84.
    Ebgert, J. H. (1916). “Epidemic pneumonia in the tropics.” NY Med J 103: 1125.Google Scholar
  85. 85.
    Ekwurzel, G. M., J. S. Simmons, H. Dublin, and L. D. Felton (1938). “Studies of immunizing substances in pneumococci. VIII. Report on field test to determine the prophylactic value of a pneumococcus antigen.” Public Health Rep 53: 1877–93.Google Scholar
  86. 86.
    Eskola, J., T. Kilpi, et al. (2001). “Efficacy of a pneumococcal conjugate vaccine against acute otitis media.” N Engl J Med 344: 403–9.PubMedGoogle Scholar
  87. 87.
    Eskola, J., A. K. Takala, et al. (1992). “Epidemiology of invasive pneumococcal infections in children in Finland.” JAMA 268: 3323–7.PubMedGoogle Scholar
  88. 88.
    Faden, H., M. Heimerl, et al. (2002). “Urinary excretion of pneumococcal cell wall polysaccharide in children.” Pediatr Infect Dis J 21: 791–3.PubMedGoogle Scholar
  89. 89.
    Farley, J. J., J. C. King, Jr., et al. (1994). “Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection.” J Pediatr 124: 853–8.PubMedGoogle Scholar
  90. 90.
    Fedson, D. S. (1985). “Improving the use of pneumococcal vaccine through a strategy of hospital-based immunization: a review of its rationale and implications.” J Am Geriatr Soc 33: 142–50.PubMedGoogle Scholar
  91. 91.
    Feikin, D. R., C. Feldman, et al. (2004). “Global strategies to prevent bacterial pneumonia in adults with HIV disease.” Lancet Infect Dis 4: 445–55.PubMedGoogle Scholar
  92. 92.
    Feikin, D. R., and K. P. Klugman (2002). “Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines.” Clin Infect Dis 35: 547–55.PubMedGoogle Scholar
  93. 93.
    Feikin, D. R., K. P. Klugman, et al. (2005). “Increased prevalence of pediatric pneumococcal serotypes in elderly adults.” Clin Infect Dis 41: 481–7.PubMedGoogle Scholar
  94. 94.
    Feldman, C. (1999). “Pneumonia in the elderly.” Clinics Chest Med 20: 563–573.Google Scholar
  95. 95.
    Feldman, C. (2001). Nonspecific host defences: mucociliary clearance and cough. Respiratory Infections. M. S. Niederman, G. A. Sarosi and J. Glossrotes. Philadelphia, Lippincott, Williams and Wilkins: 13–26.Google Scholar
  96. 96.
    Feldman, C. (2001). The role of alcohol in severe pneumonia and acute lung injury. Severe Community Acquired Pneumonia. J. Rello and K. V. Leper. Boston, Kluwer Academic Publishers: 139–152.Google Scholar
  97. 97.
    Feldman, C. (2004). “Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.” J Lab Clin Med 143: 269–83.PubMedGoogle Scholar
  98. 98.
    Feldman, C. (2005). “Pneumonia associated with HIV infection.” Curr Opin Infect Dis 18: 165–70.PubMedGoogle Scholar
  99. 99.
    Feldman, C., R. Anderson, et al. (2002). “The effects of pneumolysin and hydrogen peroxide, alone and in combination, on human ciliated epithelium in vitro.” Respir Med 96: 580–5.PubMedGoogle Scholar
  100. 100.
    Feldman, C., R. Cockeran, et al. (2006). “Hyaluronidase augments pneumolysin-mediated injury to human ciliated epithelium.” Int J Infect Dis 11: 11–15.Google Scholar
  101. 101.
    Feldman, C., M. Glatthaar, et al. (1999). “Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults.” Chest 116: 107–14.PubMedGoogle Scholar
  102. 102.
    Feldman, C., K. P. Klugman, V. L. Yu, A. Ortqvist, C. C. C Chiou, M. B. F. Chedid, J. Rello, M. Wagener, and the International Pneumococcal Study Group (2007). “Bacteremic pneumococcal pneumonia: impact of HIV on clinical presentation and outcome.” J Infect 55: 125–135.Google Scholar
  103. 103.
    Feldman, C., T. J. Mitchell, et al. (1990). “The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in vitro.” Microb Pathog 9: 275–84.PubMedGoogle Scholar
  104. 104.
    Feldman, C., N. C. Munro, et al. (1991). “Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo.” Am J Respir Cell Mol Biol 5: 416–23.PubMedGoogle Scholar
  105. 105.
    Feldman, C., R. Read, et al. (1992). “The interaction of Streptococcus pneumoniae with intact human respiratory mucosa in vitro.” Eur Respir J 5: 576–83.PubMedGoogle Scholar
  106. 106.
    Felton, L. D. (1938). “Studies on immunizing substances in pneumococci. VII. Response in human beings to antigenic pneumococcus polysaccharides, type I and II.” Public Health Rep. 53: 2855–77.Google Scholar
  107. 107.
    Fickl, H., R. Cockeran, et al. (2005). “Pneumolysin-mediated activation of NFkappaB in human neutrophils is antagonized by docosahexaenoic acid.” Clin Exp Immunol 140: 274–81.PubMedGoogle Scholar
  108. 108.
    File, T. M., Jr., H. Lode, et al. (2004). “Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.” Antimicrob Agents Chemother 48: 3323–31.PubMedGoogle Scholar
  109. 109.
    Finland, M. (1942). “Recent advances in the epidemiology of pneumococcal infections.” Med 21: 307–44.Google Scholar
  110. 110.
    Finland, M. (1979). “Pneumonia and pneumococcal infections, with special reference to pneumococcal pneumonia: The 1979 J. Burns Amberson Lecture.” Am Rev Respir Dis 120: 481–502PubMedGoogle Scholar
  111. 111.
    Finland, M., and M. W. Barnes (1978). “Changing ecology of acute bacterial empyema: Occurrence and mortality at Boston City Hospital during twelve selected years from 1935 to 1972.” J Infect Dis 157: 274–91.Google Scholar
  112. 112.
    Finland, M., and M. W. Barnes (1977). “Acute bacterial meningitis at Boston City Hospital during 12 selected years, 1935–1972.” J Infect Dis 136: 400–15.Google Scholar
  113. 113.
    Finland, M., and W. D. Sutliff (1931). “Specific cutaneous reactions and circulating antibodies in the course of lobar pneumonia. I. Cases receiving no serum therapy.” J Exp Med 54: 637–52.PubMedGoogle Scholar
  114. 114.
    Finland, M., and R. C. Tilghman (1936). “Bacteriological and immunological studies in families with pneumococcic infections: The development of type-specific antibodies in healthy contact carriers.” J Clin Invest 15: 501–8.PubMedGoogle Scholar
  115. 115.
    Finland, M., and M. W. Barnes (1977). “Changes in occurrence of capsular serotypes of Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974.” J Clin Microbiol 5: 154–66.PubMedGoogle Scholar
  116. 116.
    Flannery, B., R. T. Heffernan, et al. (2006). “Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization.” Annals Int Med 144: 1–9.Google Scholar
  117. 117.
    French, N., J. Nakiyingi, et al. (2000). “23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.” Lancet 355: 2106–11.PubMedGoogle Scholar
  118. 118.
    Fry, A. M., R. R. Facklam, et al. (2003). “Multistate evaluation of invasive pneumococcal diseases in adults with human immunodeficiency virus infection: serotype and antimicrobial resistance patterns in the United States.” J Infect Dis 188: 643–52.PubMedGoogle Scholar
  119. 119.
    Gaston, M. H., J. I. Verter, et al. (1986). “Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial.” N Engl J Med 314: 1593–9.PubMedGoogle Scholar
  120. 120.
    Gentile, J. H., M. D. Sparo, et al. (2003). “Adult bacteremic pneumococcal pneumonia acquired in the community. A prospective study on 101 patients.” Medicina (B Aires) 63: 9–14.Google Scholar
  121. 121.
    Giebink, G. S. (1981). “The pathogenesis of pneumococcal otitis media in chinchillas and the efficacy of vaccination in prophylaxis.” Rev Infect Dis 3: 342–53.PubMedGoogle Scholar
  122. 122.
    Giebink, G. S. (1985). “Preventing pneumococcal disease in children: recommendations for using pneumococcal vaccine.” Pediatr Infect Dis 4: 343–8.PubMedGoogle Scholar
  123. 123.
    Giebink, G. S., I. K. Berzins, et al. (1980). “Experimental otitis media after nasal inoculation of Streptococcus pneumoniae and influenza A virus in chinchillas.” Infect Immun 30: 445–50.PubMedGoogle Scholar
  124. 124.
    Giebink, G. S., J. V. Grebner, Y. Kim, and P. G. Quie (1978). “Severe opsonic deficiency produced by Streptococcus pneumoniae and by capsular polysaccharide antigens.” Yale J Biol Med 51: 527–38.PubMedGoogle Scholar
  125. 125.
    Giebink, G. S., C. T. Le, et al. (1981). “Serum antibody responses of high-risk children and adults to vaccination with capsular polysaccharides of Streptococcus pneumoniae.” Rev Infect Dis 3 Suppl: S168–78.PubMedGoogle Scholar
  126. 126.
    Giebink, G. S., G. Schiffman, et al. (1979). “Vaccine-type pneumococcal pneumonia. Occurrence after vaccination in an asplenic patient.” JAMA 241: 2736–7.PubMedGoogle Scholar
  127. 127.
    Gilks, C. F., S. A. Ojoo, et al. (1996). “Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya.” Lancet 347: 718–23.PubMedGoogle Scholar
  128. 128.
    Gillespie, S. H. (1989). “Aspects of pneumococcal infection including bacterial virulence, host response and vaccination.” J Med Microbiol 28: 237–48.PubMedGoogle Scholar
  129. 129.
    Gilman, B. B., and G. W. Anderson (1938). “Community outbreak of type I pneumococcus infection.” Bull. Johns Hopkins Hosp 38: 312–15.Google Scholar
  130. 130.
    Givon-Lavi, N., D. Fraser, et al. (2003). “Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings.” Pediatr Infect Dis J 22: 524–32.PubMedGoogle Scholar
  131. 131.
    Goodner, K. (1931). “Development and localization of dermal pneumococcic infection in the rabbit.” J Exp Med 54: 847–58.PubMedGoogle Scholar
  132. 132.
    Gorgas, W. C. (1913). “Sanitation on the Panama Canal.” JAMA 40: 953–55.Google Scholar
  133. 133.
    Grau, I., R. Pallares, et al. (2005). “Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.” Arch Intern Med 165: 1533–40.PubMedGoogle Scholar
  134. 134.
    Gray, B. M., G. M. Converse, 3rd, et al. (1980). “Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life.” J Infect Dis 142: 923–33.PubMedGoogle Scholar
  135. 135.
    Greenberg, D. (1919). “Relation of meteorological conditions to the prevalence of pneumonia.” AMA 72: 252–7.Google Scholar
  136. 136.
    Greenberg, D., N. Givon-Lavi, et al. (2006). “The contribution of smoking and exposure to tobacco smoke to Streptococcus pneumoniae and Haemophilus influenzae carriage in children and their mothers.” Clin Infect Dis 42: 897–903.PubMedGoogle Scholar
  137. 137.
    Handwerger, S., and A. Tomasz (1986). “Alterations in penicillin-binding proteins of clinical and laboratory isolates of pathogenic Streptococcus pneumoniae with low levels of penicillin resistance.” J Infect Dis 153: 83–9.PubMedGoogle Scholar
  138. 138.
    Hansman, D., and M. Bullen (1967). “A resistant pneumococcus.” Lancet ii: 264–65.Google Scholar
  139. 139.
    Harris, A. H., and H. S. Ingraham (1937). “Study of carrier condition associated with type II pneumonia in camp of Civilian Conservation Corps.” J Clin Invest 16: 41–8.PubMedGoogle Scholar
  140. 140.
    Hausdorff, W. P., J. Bryant, et al. (2000). “The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.” Clin Infect Dis 30: 122–40.PubMedGoogle Scholar
  141. 141.
    Hausdorff, W. P., J. Bryant, et al. (2000). “Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.” Clin Infect Dis 30: 100–21.PubMedGoogle Scholar
  142. 142.
    Hausdorff, W. P., D. R. Feikin, et al. (2005). “Epidemiological differences among pneumococcal serotypes.” Lancet Infect Dis 5: 83–93.PubMedGoogle Scholar
  143. 143.
    Health and Public Policy Committee, A. C. o. P. (1986). “Pneumococcal vaccine.” Ann Intern Med 104: 118–20.Google Scholar
  144. 144.
    Heffernan, R. T., N. L. Barrett, et al. (2005). “Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000.” J Infect Dis 191: 2038–45.PubMedGoogle Scholar
  145. 145.
    Heffron, R. (1979). Pneumonia with Special Reference to Pneumococcus Lobar Pneumonia, Cambridge, Harvard University Press.Google Scholar
  146. 146.
    Hennessy, T. W., K. M. Petersen, et al. (2002). “Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: A controlled intervention trial in rural Alaska.” Clin Infect Dis 34: 1543–50.PubMedGoogle Scholar
  147. 147.
    Hennessy, T. W., R. J. Singleton, et al. (2005). “Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity.” Vaccine 23: 5464–73.PubMedGoogle Scholar
  148. 148.
    Henrichsen, J. (1995). “Six newly recognized types of Streptococcus pneumoniae.” J Clin Microbiol 33: 2759–62.PubMedGoogle Scholar
  149. 149.
    Hirsch, E. F., and M. McKinney (1919). “An epidemic of pneumococcus bronchopneumonia.” J. Infect. Dis. 24: 594–617.Google Scholar
  150. 150.
    Hirschtick, R. E., J. Glassroth, et al. (1995). “Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group.” N Engl J Med 333: 845–51.PubMedGoogle Scholar
  151. 151.
    Hoge, C. W., M. R. Reichler, et al. (1994). “An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail.” N Engl J Med 331: 643–8.PubMedGoogle Scholar
  152. 152.
    Holle, H. A., and J. G. M. Bullowa (1940). “Pneumococcal cross-infections in home and hospital.” N Engl J Med 223: 887–890.Google Scholar
  153. 153.
    Hoshino, K., H. Watanabe, et al. (2002). “High rate of transmission of penicillin-resistant Streptococcus pneumoniae between parents and children.” J Clin Microbiol 40: 4357–9.PubMedGoogle Scholar
  154. 154.
    Hsu, H. E., K. A. Shutt, et al. (2009). “Effect of pneumococcal conjugate vaccine on pneumococcal meningitis.” N Engl J Med 360 (3): 144–56.Google Scholar
  155. 155.
    Huebner, R. E., N. Mbelle, et al. (2004). “Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine.” Vaccine 22: 2696–700.PubMedGoogle Scholar
  156. 156.
    Ivemark, B. I. (1955). “Implications of agenesis of the spleen on the pathogenesis of conotruncus anomalies in childhood; an analysis of the heart malformations in the splenic agenesis syndrome, with fourteen new cases.” Acta Paediatr 44 (Suppl 104): 7–110.Google Scholar
  157. 157.
    Jackson, L. A., K. M. Neuzil, et al. (2003). “Effectiveness of pneumococcal polysaccharide vaccine in older adults.” N Engl J Med 348: 1747–55.PubMedGoogle Scholar
  158. 158.
    Jacobs, M. R., H. J. Koornhof, et al. (1978). “Emergence of multiply resistant pneumococci.” N Engl J Med 299: 735–40.PubMedGoogle Scholar
  159. 159.
    Jaffe, A., and I. M. Balfour-Lynn (2005). “Management of empyema in children.” Pediatr Pulmonol 40: 148–56.PubMedGoogle Scholar
  160. 160.
    Janoff, E. N., R. F. Breiman, et al. (1992). “Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives.” Ann Intern Med 117: 314–24.PubMedGoogle Scholar
  161. 161.
    Johnston, H. (1938). “Pneumonia as contagious disease.” Can Med Assoc J 38: 270–271.Google Scholar
  162. 162.
    Jones, N., R. Huebner, et al. (1998). “The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population.” Aids 12: 2177–84.PubMedGoogle Scholar
  163. 163.
    Kass, E. H. (1981). “Assessment of the pneumococcal polysaccharide vaccine: A workshop held at the Harvard Club of Boston.” Rev. Infect. Dis. 3 (suppl.): S1-S197.Google Scholar
  164. 164.
    Kass, E. H., G. M. Green, and E. Goldstein (1966). “Mechanism of antibacterial action in the respiratory tract.” Bacteriol Rev 30: 488–496.PubMedGoogle Scholar
  165. 165.
    Kaufman, P. (1947). “Pneumonia in old age. Active immunization against pneumonia with pneumococcus polysaccharides: Results of a six year study.” Arch Intern Med 79: 518–531.Google Scholar
  166. 166.
    Kayhty, H., H. Ahman, et al. (1995). “Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children.” J Infect Dis 172: 1273–8.PubMedGoogle Scholar
  167. 167.
    Kilpi, T., H. Ahman, et al. (2003). “Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.” Clin Infect Dis 37: 1155–64.PubMedGoogle Scholar
  168. 168.
    Klein, J. O. (1981). “The epidemiology of pneumococcal disease in infants and children.” Rev Infect Dis 3: 246–53.PubMedGoogle Scholar
  169. 169.
    Klugman, K. P. (1990). “Pneumococcal resistance to antibiotics.” Clinical Microbiology Reviews 3: 171–96.PubMedGoogle Scholar
  170. 170.
    Klugman, K. P. (2001). “Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance.” Lancet Infect Dis 1: 85–91.PubMedGoogle Scholar
  171. 171.
    Klugman, K. P. (2002). “Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections.” Eur Respir J Suppl 36: 3s - 8s.PubMedGoogle Scholar
  172. 172.
    Klugman, K. P., and C. Feldman (2001). “Streptococcus pneumoniae respiratory tract infections.” Curr Opin Infect Dis 14: 173–9.PubMedGoogle Scholar
  173. 173.
    Klugman, K. P., S. A. Madhi, et al. (2003). “A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.” N Engl J Med 349: 1341–8.PubMedGoogle Scholar
  174. 174.
    LaForce, F. M., and T. C. Eickhoff (1986). “Pneumococcal vaccine: the evidence mounts.” Ann Intern Med 104: 110–2.PubMedGoogle Scholar
  175. 175.
    Lazarus, H. M., M. Lederman, et al. (1980). “Pneumococcal vaccination: the response of patients with multiple myeloma.” Am J Med 69: 419–23.PubMedGoogle Scholar
  176. 176.
    Leach, A. J., and P. S. Morris (2001). “Perspectives on infective ear disease in indigenous Australian children.” J Paediatr Child Health 37: 529–30.PubMedGoogle Scholar
  177. 177.
    Leimkugel, J., A. Adams Forgor, et al. (2005). “An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics.” J Infect Dis 192: 192–9.PubMedGoogle Scholar
  178. 178.
    Lipsitch, M., C. G. Whitney, et al. (2005). “Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?” PLoS Med 2: e15.PubMedGoogle Scholar
  179. 179.
    Lister, F. S. (1913). “Specific serological reactions with pneumococci from different sources,.” Publ S Afr Inst Med Res 1: 1–14.Google Scholar
  180. 180.
    Lister, F. S. (1916). “An experimental study of prophylactic inoculation against pneumococcal infection in the rabbit and in man.” Publ S Afr Inst Med Res 1: 231–87.Google Scholar
  181. 181.
    Lister, F. S. (1917). “Prophylactic inoculation of man against pneumococcal infections, and more particularly against lobar pneumonia.” Publ S Afr Ins. Med Res 10: 304–22.Google Scholar
  182. 182.
    Lister, S., and D. Ordman (1935). “Epidemiology of pneumonia on the Witwatersrand goldfields and prevention of pneumonia and other acute respiratory diseases in native laborers in South Africa by means of vaccine.” Publ S Afr Inst Med Res 7: 1–124.Google Scholar
  183. 183.
    Lonks, J. R., J. Garau, et al. (2002). “Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae.” Clin Infect Dis 35: 556–64.PubMedGoogle Scholar
  184. 184.
    Lopez, R., and E. Garcia (2004). “Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes, and bacteriophage.” FEMS Microbiol Rev 28: 553–80.PubMedGoogle Scholar
  185. 185.
    Lowell, F. C., E. Strauss,and M. Finland (1940). “Observations on the susceptibility of pneumococci to sulfapyridine, sulfathiazole and sulfamethoxazole.” Ann. Intern. Med. 14: 1001–23.Google Scholar
  186. 186.
    Lund, E. (1970). “Types of pneumococci found in blood, spinal fluid and pleural exudate during a period of 15 years (1954–1969).” Acta Pathol Microbiol Scand [B] Microbiol Immunol 78: 333–6.Google Scholar
  187. 187.
    MacLeod, C. M., R. G. Hodges, M. Heidelberger, and W. G. Bernhard (1945). “Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides.” J Exp Med 82: 445–65.Google Scholar
  188. 188.
    Madhi, S. A., and K. P. Klugman (2004). “A role for Streptococcus pneumoniae in virus-associated pneumonia.” Nat Med 10: 811–3.PubMedGoogle Scholar
  189. 189.
    Madhi, S. A., M. Kohler, et al. (2006). “Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia.” Pediatr Infect Dis J 25: 30–6.PubMedGoogle Scholar
  190. 190.
    Madhi, S. A., L. Kuwanda, et al. (2005). “The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.” Clin Infect Dis 40: 1511–8.PubMedGoogle Scholar
  191. 191.
    Madhi, S. A., H. Ludwick, et al. (2006). “Pneumococcal co – infection with human metapneumovirus.” J Infect Dis 193: 1236–43.PubMedGoogle Scholar
  192. 192.
    Malley, R., K. Trzcinski, et al. (2005). “CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization.”Proc Natl Acad Sci USA 102: 4848–53.PubMedGoogle Scholar
  193. 193.
    Martinez, J. A., J. P. Horcajada, et al. (2003). “Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.” Clin Infect Dis 36: 389–95.PubMedGoogle Scholar
  194. 194.
    Maynard, G. D. (1913). “An enquiry into the etiology, manifestations and prevention of pneumonia amongst natives on the Rand from tropical areas.” Publ. S. Afr. Inst. Med. Res. 1: 1–101.Google Scholar
  195. 195.
    Mbelle, N., R. E. Huebner, et al. (1999). “Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine.” J Infect Dis 180: 1171–6.PubMedGoogle Scholar
  196. 196.
    McGee, L., L. McDougal, et al. (2001). “Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network.” J Clin Microbiol 39: 2565–71.PubMedGoogle Scholar
  197. 197.
    McGowan, J. E., Jr., M. W. Barnes, et al. (1975). “Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935–1972), with special reference to hospital-acquired cases.” J Infect Dis 132: 316–35.PubMedGoogle Scholar
  198. 198.
    McGowan, J. E., Jr., L. Bratton, et al. (1973). “Bacteremia in febrile children seen in a ”walk-in“ pediatric clinic.” N Engl J Med 288: 1309–12.PubMedGoogle Scholar
  199. 199.
    Moore, H. F., and A. M. Chesney (1918). “A further study of ethylhydrocupreine (optochin) in the treatment of acute lobar pneumonia.” Arch. Intern. Med. 21: 659–81.Google Scholar
  200. 200.
    Mufson, M. A. (1981). “Pneumococcal infections.” JAMA 246: 1942–8.PubMedGoogle Scholar
  201. 201.
    Mufson, M. A., R. J. Staneck. (1999). “Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978–1997.” Am J Med 107 Suppl 1A: 34S-43S.PubMedGoogle Scholar
  202. 202.
    Navin, T. R., D. Rimland, et al. (2000). “Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus.” J Infect Dis 181: 158–64.PubMedGoogle Scholar
  203. 202.
    Netter (1888). “Contagion de la pneumonie.” Arch Gen Med (Paris) 2122: 530–44, 699–718; 42–59.Google Scholar
  204. 204.
    Neufeld, F. (1900). “Ueber eine specifische bakteriolytische Wirkung der Galle.” Z Hyg Infektionskr 34: 454–464.Google Scholar
  205. 205.
    Neufeld, F. (1902). “Ueber die Agglutination der Pneumokokken und Ueber die Theorien der Agglutination.” Z Hyg Infektionskr 40: 54–72.Google Scholar
  206. 206.
    Nuorti, J. P., J. C. Butler, et al. (2000). “Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team.” N Engl J Med 342: 681–9.PubMedGoogle Scholar
  207. 207.
    Nuorti, J. P., J. C. Butler, et al. (2000). “Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California.” Ann Intern Med 132: 182–90.PubMedGoogle Scholar
  208. 208.
    O’Brien, K. L., L. H. Moulton, et al. (2003). “Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial.” Lancet 362: 355–61.PubMedGoogle Scholar
  209. 209.
    O’Brien, K. L. and H. Nohynek (2003). “Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae.” Pediatr Infect Dis J 22: e1–11.PubMedGoogle Scholar
  210. 210.
    Opie, E. L., F. G. Blake, J. C. Small, and T. M. Rivers (1921). Epidemic Respiratory Disease: The Pneumonias and Other Infections of the Respiratory Tract Accompanying Influenza and Measles. St. Louis, C.V. MosbyGoogle Scholar
  211. 211.
    Ordman, D. (1931). “Pneumonia in the native mine workers of the Wit-watersrand goldfields: a bacteriological and epidemiological study.” J Med Assoc S Afr 5: 108–116.Google Scholar
  212. 212.
    Ordman, D. (1935). “Pneumonia in the native mine labourers of northern Rhodesia copperfields with an account of an experiment in pneumonia prophylaxis by means of a vaccine at the Roan Antelope Mine.” Publ S Afr Inst Med Res 7: 1–124.Google Scholar
  213. 213.
    Ordman, D. (1937). “Pneumococcus typing: its value in pneumonia.” S Afr Med J 11: 569–73.Google Scholar
  214. 214.
    Ordman, D. (1938). “Pneumococcus types in South Africa: a study of their occurrence and the effect thereon of prophylactic inoculation.” Pub. S Afr Inst Med Res 9: 1–27.Google Scholar
  215. 215.
    Orenstein, A. J. (1931). “Vaccine prophylaxis in pneumonia: a review of fourteen years’ experience with inoculation of native mine workers on the Witwatersrand against pneumonia.” J Med Assoc S Afr 5: 339–46.Google Scholar
  216. 216.
    Pai, R., M. R. Moore, et al. (2005). “Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States.” J Infect Dis 192: 1988–95.PubMedGoogle Scholar
  217. 217.
    Pallares, R., J. Linares, et al. (1995). “Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.” New Engl J Med 333: 474–80.PubMedGoogle Scholar
  218. 218.
    Park, J. H., Jr., and H. T. Chickering (1919). “Type I pneumococcal lobar pneumonia among Puerto Rican laborers of Camp Jackson, South Carolina.” JAMA 73: 183–6.Google Scholar
  219. 219.
    Park, I. H., D. G. Pritchard, et al. (2007). “Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae.” J Clin Microbiol 45(4): 1225–33Google Scholar
  220. 220.
    Park, I. H., S. Park, et al (2007). “Genetic basis for the new pneumococcal serotype, 6C”. Infect Immun 75 (9): 4482–9.Google Scholar
  221. 221.
    Paton, J. C., A. M. Berry, et al. (2000). Molecular analysis of putative pneumococcal virulence proteins. Streptococcus pneumoniae. Molecular Biology and Mechanisms of Disease. A. Tomasz. New York, Mary Ann Liebert Inc: 261–70.Google Scholar
  222. 222.
    Patrick, K. M., and F. R. Woolley (1981). “A cost-benefit analysis of immunization for pneumococcal pneumonia.” JAMA 245:473–7.PubMedGoogle Scholar
  223. 223.
    Pearson, H. A. (1980). “Splenectomy: its risks and its roles.” Hosp Pract 15: 85–9, 92–4.Google Scholar
  224. 224.
    Peltola, V. T., and J. A. McCullers (2004). “Respiratory viruses predisposing to bacterial infections: role of neuraminidase.” Pediatr Infect Dis J 23 Suppl 1: S87–97.PubMedGoogle Scholar
  225. 225.
    Perlino, C. A., and D. Rimland (1985). “Alcoholism, leukopenia, and pneumococcal sepsis.” Am Rev Respir Dis 132: 757–60.PubMedGoogle Scholar
  226. 226.
    Peterson, L. R. (2006). “Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?” Clin Infect Dis 42: 224–33.PubMedGoogle Scholar
  227. 227.
    Prymula, R., P. Peeters, et al. (2006). “Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.” Lancet 367: 740–8.PubMedGoogle Scholar
  228. 228.
    Quie, P. G., G. S. Giebink, and J. A. Winkelstein (1981). “The pneumococcus. A symposium held at the Kroc Foundation headquarters, Santa Ynez Valley, California, February 25–29, 1980.” Rev Infect Dis 3: 183–395.Google Scholar
  229. 229.
    Redd, S. C., G. W. Rutherford, 3rd, et al. (1990). “The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents.” J Infect Dis 162: 1012–7.PubMedGoogle Scholar
  230. 230.
    Regev-Yochay, G., R. Dagan, et al. (2004). “Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in children.” JAMA 292: 716–20.PubMedGoogle Scholar
  231. 231.
    Riley, I. D., and R. M. Douglas (1981). “An epidemiologic approach to pneumococcal disease.” Rev Infect Dis 3: 233–45.PubMedGoogle Scholar
  232. 232.
    Robertson, O. H. (1931). “Instance of lobar pneumonia acquired in the laboratory.” J Prev Med 5: 221–4.Google Scholar
  233. 233.
    Rogers, L. (1925). “Relationship between pneumonia incidence and climate in India.” Lancet 1: 1173–7.Google Scholar
  234. 234.
    Roson, B., N. Fernandez-Sabe, et al. (2004). “Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia.” Clin Infect Dis 38: 222–6.PubMedGoogle Scholar
  235. 235.
    Rytel, M. W., T. H. Dee, et al. (1974). “Possible pathogenetic role of capsular antigens in fulminant pneumococcal disease with disseminated intravascular coagulation (DIC).” Am J Med 57: 889–96.PubMedGoogle Scholar
  236. 236.
    Sabin, A. B. (1929). “ “Stained slide” microscopic agglutination test: Application to (1) rapid typing of pneumococci, (2) determination of antibody.” Am J Public Health 19: 1148–50.Google Scholar
  237. 237.
    Schiffman, G. (1981). “Immune responses to pneumococcal polysaccharide antigens: a comparison of the murine model and the response in humans.” Rev Infect Dis 3: 224–32.PubMedGoogle Scholar
  238. 238.
    Schiffman, G., R. M. Douglas, et al. (1980). “A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques.” J Immunol Methods 33: 133–44.PubMedGoogle Scholar
  239. 239.
    Schuchat, A., K. Robinson, J. D. Wenger, L. E. Harrison, M. Farley, A. L. Reingold, L. Lefkowitz, and B. A. Perkins (1997). “For the active surveillance team, Bacterial meningitis in the United States in 1995.” N Engl J Med 337: 970–76.PubMedGoogle Scholar
  240. 240.
    Schwartz, J. S. (1982). “Pneumococcal vaccine: clinical efficacy and effectiveness.” Ann Intern Med 96: 208–20.PubMedGoogle Scholar
  241. 241.
    Sell, S. H., P. F. Wright, et al. (1981). “Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines.” Rev Infect Dis 3 Suppl: S97–107.PubMedGoogle Scholar
  242. 242.
    Selwyn, P. A., A. R. Feingold, et al. (1988). “Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS.” Aids 2: 267–72.PubMedGoogle Scholar
  243. 243.
    Shapiro, E. D. (1987). “Pneumococcal vaccine failure [letter].” N Engl J Med 316: 1272–3.Google Scholar
  244. 244.
    Shapiro, E. D., A. T. Berg, et al. (1991). “The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.” N Engl J Med 325: 1453–60.PubMedGoogle Scholar
  245. 245.
    Shapiro, E. D., and J. D. Clemens (1984). “A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections.” Ann Intern Med 101: 325–30.PubMedGoogle Scholar
  246. 246.
    Simberkoff, M. S., A. P. Cross, et al. (1986). “Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.” N Engl J Med 315: 1318–27.PubMedGoogle Scholar
  247. 247.
    Simberkoff, M. S., M. Lukaszewski, et al. (1986). “Antibiotic-resistant isolates of Streptococcus pneumoniae from clinical specimens: a cluster of serotype 19A organisms in Brooklyn, New York.” J Infect Dis 153: 78–82.PubMedGoogle Scholar
  248. 248.
    Singhal, A., M. K. Lalitha, et al. (1996). “Modified latex agglutination test for rapid detection of Streptococcus pneumoniae and Haemophilus influenzae in cerebrospinal fluid and direct serotyping of Streptococcus pneumoniae.” Eur J Clin Microbiol Infect Dis 15: 472–7.PubMedGoogle Scholar
  249. 249.
    Sisk, J. E., and R. K. Riegelman (1986). “Cost effectiveness of vaccination against pneumococcal pneumonia: an update.” Ann Intern Med 104: 79–86.PubMedGoogle Scholar
  250. 250.
    Small, A. A. (1918). “Pneumonia at a base hospital: observations in one thousand and one hundred cases at Camp Pike, Ark.” JAMA 71: 700–702.Google Scholar
  251. 251.
    Smillie, W. E. (1936). “Study of an outbreak of type II pneumococcus pneumonia in Veterans’ Administration Hospital at Bedford, Massachusetts.” Am J Hyg 24: 522–535.Google Scholar
  252. 252.
    Smillie, W. E. (1938). “Study of a type I pneumococcus epidemic at the State Hospital at Worcester, Mass.” Am J Public Health 28: 293–302.Google Scholar
  253. 253.
    Smit, P., D. Oberholzer, et al. (1977). “Protective efficacy of pneumococcal polysaccharide vaccines.” JAMA 238: 2613–6.PubMedGoogle Scholar
  254. 254.
    Song, J. H., S. I. Jung, et al. (2004). “Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens.” Clin Infect Dis 38: 1570–8.PubMedGoogle Scholar
  255. 255.
    Ssali, F. N., M. R. Kamya, et al. (1998). “A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda.” J Acquir Immune Defic Syndr Hum Retrovirol 19: 484–9.PubMedGoogle Scholar
  256. 256.
    Stephens, D. S., S. M. Zughaier, et al. (2005). “Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population – based assessment.” Lancet 365: 855–63.PubMedGoogle Scholar
  257. 257.
    Stillman, E. G. (1930). “Susceptibility of rabbits to infection by the inhalation of type II pneumococcus.” J Exp Med 52: 215–24.PubMedGoogle Scholar
  258. 258.
    Stillman, E. G., and A. Branch (1924). “Experimental production of pneumococcus pneumonia in mice by inhalation method.” J Exp Med 40: 733–42.PubMedGoogle Scholar
  259. 259.
    Stralin, K., M. S. Kaltoft, et al. (2004). “Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community-acquired pneumonia.” J Clin Microbiol 42: 3620–5.PubMedGoogle Scholar
  260. 260.
    Styrt, B. (1990). “Infection associated with asplenia: risks, mechanisms, and prevention.” Am J Med 88 (5 N): 33 N–42 N.Google Scholar
  261. 261.
    Sydenstricker, V. P. W., and A. C. Sutton (1918). “An epidemiological study of lobar pneumonia.” Bull Johns Hopkins Hosp. 38:312–15.Google Scholar
  262. 262.
    Takahashi, H., K. Oishi, et al. (2003). “Decreased serum opsonic activity against Streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults.” Clin Infect Dis 37 (11): 1534–40.PubMedGoogle Scholar
  263. 263.
    Talbot, T. R., K. A. Poehling, et al. (2004). “Reduction in high rates of antibiotic – nonsusceptible invasive pneumococcal disease in Tennessee following introduction of the pneumococcal conjugate vaccine.” Clin Infect Dis 39: 641–48.PubMedGoogle Scholar
  264. 264.
    Tan, T. Q., E. O. Mason, Jr., et al. (2002). “Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae.” Pediatrics 110: 1–6.PubMedGoogle Scholar
  265. 265.
    Teele, D. W., S. I. Pelton, et al. (1975). “Bacteremia in febrile children under 2 years of age: results of cultures of blood of 600 consecutive febrile children seen in a ”walk-in“ clinic.” J Pediatr 87: 227–30.PubMedGoogle Scholar
  266. 266.
    Tenny, C. F., and W. T. Rivenburgh (1919). “A group of 68 cases of type I pneumonia occurring in 30 days at Camp Upton.” Arch Intern Med 24: 545–52.Google Scholar
  267. 267.
    Terrell, E. E., O. H. Robertson, and L. T. Coggeshall (1933). “Experimental pneumococcus lobar pneumonia in the dog. I. Method of production and course of disease.” J. Clin. Invest. 12: 393–432.PubMedGoogle Scholar
  268. 268.
    The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group (1991). “Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection.” N Engl J Med 325: 73–80.Google Scholar
  269. 269.
    Tilghman, R. C., and M. Finland (1937). “Clinical significance of bacteremia in pneumococcal pneumonia.” Arch. Intern. Med. 59: 602–19.Google Scholar
  270. 270.
    Tomasz, A. (1981). “Surface components of Streptococcus pneumoniae.” Rev Infect Dis 3: 190–211.PubMedGoogle Scholar
  271. 271.
    Tomasz, A. (1995). “The pneumococcus at the gates.” N Engl J Med 333: 514–5.PubMedGoogle Scholar
  272. 272.
    Tomasz, A. (2000). Streptococcus pneumoniae: Molecular Biology & Mechanisms of Disease. New York, Mary Ann Liebert.Google Scholar
  273. 273.
    Tomforde (1902). “Eine Endemie von croupöser Pneumonie im Dorfe Laumuhlen, Kreis Neuhaus an der Oste, Januar 1902,.” Dtsch Med Wochenschr 28: 577–9.Google Scholar
  274. 274.
    Tumbarello, M., E. Tacconelli, et al. (1998). “Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators.” J Acquir Immune Defic Syndr Hum Retrovirol 18: 39–45.PubMedGoogle Scholar
  275. 275.
    Tuomanen, E. I., R. Austrian, et al. (1995). “Pathogenesis of pneumococcal infection.” N Engl J Med 332: 1280–4.PubMedGoogle Scholar
  276. 276.
    Vanderkooi, O. G., D. E. Low, et al. (2005). “Predicting antimicrobial resistance in invasive pneumococcal infections.” Clin Infect Dis 40: 1288–97.PubMedGoogle Scholar
  277. 277.
    Verhoef, J. (1982). Effects of nutrition of antibiotic action, in:Action of Antibiotics in Patients. Bern, Huber.Google Scholar
  278. 278.
    Waldman, J. D., A. Rosenthal, et al. (1977). “Sepsis and congenital asplenia.” J Pediatr 90: 555–9.PubMedGoogle Scholar
  279. 279.
    Wara, D. W. (1981). “Host defense against Streptococcus pneumoniae: the role of the spleen.” Rev Infect Dis 3: 299–309.PubMedGoogle Scholar
  280. 280.
    Waterer, G. W. (2005). “Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia.” Curr Opin Infect Dis 18: 157–63.PubMedGoogle Scholar
  281. 281.
    Waterer, G. W., G. W. Somes, et al. (2001). “Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 6: 1837–42.Google Scholar
  282. 282.
    Watson, D. A., and D. M. Musher (1999). “A brief history of the pneumococcus in biomedical research.” Semin Respir Infect 14: 198–208.PubMedGoogle Scholar
  283. 283.
    Weiss, K., D. E. Low, et al. (2004). “Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults.” Can Respir J 11:589–93.PubMedGoogle Scholar
  284. 284.
    Wenger, J. D., A. W. Hightower, et al. (1990). “Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group.” J Infect Dis 162: 1316–23.Google Scholar
  285. 285.
    Wernette, C. M., C. E. Frasch, et al. (2003). “Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.” Clin Diagn Lab Immunol 10 514–9.PubMedGoogle Scholar
  286. 286.
    Whitby, L. (1938). “Chemotherapy of bacterial infections (Bradshaw Lecture).” Lancet 2: 1095–103.Google Scholar
  287. 287.
    White, B. (1938). The Biology of Pneumococcus: The Bacteriological, Biochemical and Immunological Characters and Activities of Diplococcus pneumoniae. New York, Harvard University Press.Google Scholar
  288. 288.
    Whitney, C. G., M. M. Farley, et al. (2003). “Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.” N Engl J Med 348: 1737–46.PubMedGoogle Scholar
  289. 289.
    WHO (2005). World Health Report. Geneva, Switzerland, World Health Organization .Google Scholar
  290. 290.
    Williams, B. G., E. Gouws, et al. (2002). “Estimates of world -wide distribution of child deaths from acute respiratory infections.” Lancet Infect Dis 2: 25–32.PubMedGoogle Scholar
  291. 291.
    Winkelstein, J. A. (1981). “The role of complement in the host’s defense against Streptococcus pneumoniae.” Rev Infect Dis 3: 289–98.PubMedGoogle Scholar
  292. 292.
    Wright, A. E., W. Morgan, L. Colbrook, and R. W. Dodgson (1914). “Observations on prophylactic inoculations against pneumococcus infection, and on the results which have been achieved by it.” Lancet 1: 1–10, 87–95.Google Scholar
  293. 293.
    Yamamoto, L. G. (2001). “Revising the decision analysis for febrile children at risk for occult bacteremia in a future era of widespread pneumococcal immunization.” Clin Pediatr (Phila) 40: 583–94.Google Scholar
  294. 294.
    Yu, V. L., C. C. Chiou, et al. (2003). “An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.” Clin Infect Dis 37: 230–7.PubMedGoogle Scholar
  295. 295.
    Zighelboim, S., and A. Tomasz (1981). “Multiple antibiotic resistance in South African strains of Streptococcus pneumoniae: mechanism of resistance to beta-lactam antibiotics.” Rev Infect Dis 3: 267–76.PubMedGoogle Scholar

Suggested Reading

  1. Austrian, R., and Gold, J., Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia, Ann Intern Med 60: 759–76 (1964).PubMedGoogle Scholar
  2. Heffron, R., Pneumonia with Special Reference to Pneumococcal Lobar Pneumonia, Commonwealth Fund, New York, 1939; reprinted by Harvard University Press, 1979.Google Scholar
  3. White, B. (with the collaboration of Robinson, E. S., and Barnes, L. A.), The Biology of Pneumococcus: The Bacteriological, Biochemical and Immunological Characters and Activities of Diplococcus pneumoniae, Commonwealth Fund, New York, 1938; reprinted by Harvard University Press, 1979.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Keith P. Klugman
    • 1
  • Charles Feldman
    • 2
  1. 1.William H Foege Professor of Global Health, Hubert Department of Global Health, Rollins School of Public Health and Division of Infectious DiseasesSchool of Medicine, Emory UniversityAtlantaUSA
  2. 2.Division of Pulmonology, Department of Medicine, Faculty of Health Sciences, School of Clinical MedicineJohannesburg Hospital and University of the WitwatersrandSouth Africa

Personalised recommendations